Reaction
Myelodysplastic Syndrome Transformation reporting signals
As of the last recalculation, Myelodysplastic Syndrome Transformation appears in 519 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE (PRR 231.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Azacitidine | 129 | 231.7 | 232.7 |
| Deferasirox | 89 | 162.3 | 162.8 |
| Tretinoin | 29 | 151.7 | 152.2 |
| Mercaptopurine | 18 | 43.1 | 43.1 |
| Cytarabine | 45 | 32.8 | 32.8 |
| Azacitidine For | 14 | 31.7 | 31.7 |
| Hydroxyurea | 14 | 27.3 | 27.3 |
| Lenalidomide | 150 | 19.6 | 19.6 |
| Romiplostim | 6 | 16.2 | 16.2 |
| Olaparib | 8 | 15.6 | 15.6 |